GREENVILLE, S.C., Jan. 26 /PRNewswire-FirstCall/ -- Signalife, Inc. Signalife, Inc. announced that it has completed the development of a prototype device to be utilized for objective evaluation of ECG/IC (Electrocardiogram and Intracardiac) data Recorders. This device will be utilized to provide industry with an objective measurement of an ECG systems ability to precisely measure the electrical activity of the heart. This mechanism for evaluating all ECG systems will provide physicians, hospitals, and other end users with valuable information regarding the clinical efficacy of various ECG systems across the market which will allow them to better evaluate their future purchasing decisions.
Dr. Budimir S. Drakulic, the inventor of the company's technologies and its Chief Technology Officer, stated: "We are very excited to develop this unique device. From the Company's inception, our intent was to objectively evaluate our patented signal processing technology against other competitive devices on the market. A new arbitrary waveform generator for Intracardiac and surface Electrocardiographic signals will allow objective evaluation of recording systems in their ability to faithfully reproduce the ECG/IC signal. This new device will generate wave shapes that the investigator determines are important for specific evaluation and comparison across the industry. Some of the data comparison was reported during the Heart Rhythm Society Meeting at Boston in May of 2006, and we intend to publish additional findings in various clinical journals."
The objective valuation of ECG technologies permitted by the use of the Signalife simulator reveals what the R&D staff has exerted and what members of the medical community have underscored in terms of -- once and for all -- getting to the bottom of cardiovascular disease and its costs and injury to our society every year.
About Signalife
Signalife, Inc, is a life sciences company focused on the monitoring and detection of disease through continuous biomedical signal monitoring. Signalife uses its patented signal technology to design and develop medical devices that simplify and reduce the costs of diagnostic testing and patient monitoring in an ambulatory setting.
Signalife is publicly traded on the American Stock Exchange under the symbol SGN. The website for the company is http://www.Signalife.com. Clear Data. Trusted Results.
Caution Regarding Forward-Looking Statements
Statements in this release that are not strictly historical are "forward- looking" statements. Forward-looking statements involve known and unknown risks, which may cause Signalife's actual results in the future to differ materially from expected results. Factors which could cause or contribute to such differences include, but are not limited to, failure to complete the development and introduction of heart monitoring and other biomedical devices incorporating Signalife's technology, failure to obtain federal or state regulatory approvals governing heart monitoring and other biomedical devices incorporating Signalife's technology, inability to obtain physician, patient or insurance acceptance of for heart monitoring and other biomedical incorporating Signalife's technology, and the unavailability of financing to complete management's plans and objectives, including the development of heart monitoring and other biomedical incorporating Signalife's technology. These risks are qualified in their entirety by cautionary language and risk factors set forth and to be further described in Signalife's filings with the Securities and Exchange Commission.
Signalife, Inc.CONTACT: Kevin Kading, +1-212-918-4606, Cell - +1-917-575-1920,kdng@prodigy.net